Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 598
- 试验地点
- 1
- 主要终点
- Incidence of repeat pregnancy
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) program in increasing contraceptive use and reducing repeat pregnancies among pregnant and parenting adolescents in central Ohio.
详细描述
The risk for teen pregnancy is especially high among teen mothers, leading, in some cases, to unsafe intervals between teen births. The Teen Options to Prevent Pregnancy (T.O.P.P.) program is an 18-month clinic-based program that aims to reduce repeat pregnancies among pregnant and parenting adolescents by providing telephone-based care coordination and mobile contraceptive services to this high-risk population. This study uses a randomized controlled design to compare the effectiveness of T.O.P.P. versus usual care provided to patients at participating clinics. Study participants will be adolescent mothers between the ages of 10 to 19 recruited through seven OhioHealth women's health clinics and three OhioHealth hospitals covering seven counties in central Ohio. This study is being conducted as part of the national Evaluation of Adolescent Pregnancy Prevention Approaches funded by the U.S. Department of Health and Human Services' Office of Adolescent Health.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 19 Years(Child, Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •10 - 19 years old
- •28 weeks pregnant through 8 week post partum
- •Medicaid recipient
- •English speaking
- •Patient of OhioHealth
排除标准
- 未提供
研究组 & 干预措施
Usual care services
Teen Options to Prevent Pregnancy
干预措施: Teen Options to Prevent Pregnancy (T.O.P.P.) (Behavioral)
结局指标
主要结局
Incidence of repeat pregnancy
时间窗: 30 months after baseline
次要结局
- Contraceptive Use(30 months after baseline)
- Contraceptive Use(6 months after baseline)
- Contraceptive Use(18 months after baseline)
